Biotech Theravance (NASDAQ: THRX) is undergoing a radical transformation. Is this special situation a unique opportunity for dividend investors, or arre problems lurking beneath the surface.
Theravance recently split in two, with the money it earns fromsucessful COPD drugs continuing under the old ticker and paid out as a juicy dividend, while the drug-development arm is reborn as Theravance Biopharma.
In this video, Motley Fool Healthcare analyst David Williamson evaluates the dividend stock using a World Cup inspired grading system: a yellow card is a warning for investors, a red card is an ejection, and a "goal" happens if the stock looks like a winner.
Watch and find out the current strengths and weaknesses of Theravance and if investtors should jump on this special dividend situation.
